2026-04-17 · glp-1, tirzepatide, mounjaro, prescription

Mounjaro for Weight Loss

Key takeaways

• Mounjaro is the brand name for tirzepatide, a once-weekly injection made by Eli Lilly and FDA-approved for type 2 diabetes. It is the same molecule as Zepbound, which is approved specifically for chronic weight management.
• In clinical trials (SURMOUNT program), participants taking the highest dose of tirzepatide lost an average of 15 to 21 percent of their body weight over 72 weeks.
• Mounjaro works by activating two gut-hormone receptors (GIP and GLP-1), which reduces appetite, slows stomach emptying, and improves blood sugar control.
• Common side effects include nausea, diarrhea, vomiting, and constipation, especially during dose escalation. Serious risks include pancreatitis, gallbladder issues, and a boxed warning for thyroid C-cell tumors.
• List price is roughly $1,000 or more per month. Insurance coverage for weight loss use is limited compared to coverage for type 2 diabetes.

Who this is for

Good fit if:

• You have heard the name Mounjaro from your doctor, advertising, or social media and want to understand what it is, how it works, and whether it could help with weight loss.
• You have type 2 diabetes and your prescriber is considering Mounjaro, or you are exploring whether this medication might also support weight management.
• You want to understand the difference between Mounjaro and Zepbound before talking to your care team.

Not a fit if:

• You have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
• You have a history of pancreatitis or severe gastrointestinal disease without specialist clearance.
• You are pregnant, breastfeeding, or planning pregnancy in the near term.

What is Mounjaro?

Mounjaro is the U.S. brand name for tirzepatide, manufactured by Eli Lilly. The FDA approved Mounjaro in May 2022 for the treatment of type 2 diabetes in adults, as an addition to diet and exercise. Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning it acts on two gut-hormone pathways involved in appetite regulation and blood sugar control.

Although Mounjaro is not FDA-approved for weight loss, many prescribers use it off-label for weight management given the strong weight loss results from clinical trials. Eli Lilly later introduced Zepbound, which is the same tirzepatide molecule approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition.

For a broader view of the tirzepatide molecule and its uses, see tirzepatide for weight loss. For an overview of this drug class, see the GLP-1 weight loss overview.

How does Mounjaro work?

Tirzepatide activates receptors for two hormones your gut normally releases after eating: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Acting on both pathways produces several effects:

• Reduces appetite. Signals in the brain that drive hunger and food cravings are dampened, making it easier to eat less without constant hunger.
• Slows gastric emptying. Food stays in the stomach longer, so meals feel more filling for a longer period.
• Improves insulin sensitivity. Blood sugar control improves after meals, which is the primary reason Mounjaro was approved for type 2 diabetes.

These combined effects typically lead to meaningful reductions in calorie intake. Mounjaro works best alongside structured nutrition and physical activity; it is not a substitute for lifestyle changes.

Expected weight loss results

The SURMOUNT clinical trial program provides the most robust data on weight loss with tirzepatide.

SURMOUNT-1 (published in the New England Journal of Medicine, 2022) studied adults with obesity or overweight (without type 2 diabetes) over 72 weeks. Average total body weight loss by dose:

• 5 mg weekly: approximately 15% of body weight
• 10 mg weekly: approximately 19.5% of body weight
• 15 mg weekly: approximately 20.9% of body weight
• Placebo: approximately 3.1% of body weight

SURMOUNT-2 (published in The Lancet, 2023) studied adults with overweight or obesity who also had type 2 diabetes. Average weight loss at 72 weeks was lower (roughly 12 to 15 percent), which is consistent with patterns seen across GLP-1 class medications in people with diabetes.

These are clinical trial averages. Individual results will vary based on starting weight, dose tolerance, adherence, diet, and physical activity. Most people notice early appetite changes in the first few weeks, with steady weight loss accumulating over several months. As with other medications in this class, stopping tirzepatide is associated with gradual weight regain unless a maintenance plan is in place.

Dosing and administration

Mounjaro is a subcutaneous injection given once a week, on the same day each week, in the stomach, thigh, or upper arm. It is supplied as a single-dose pen.

Typical dose escalation schedule:

• Start at 2.5 mg once weekly for 4 weeks. This is a starter dose intended to reduce initial side effects and is not a maintenance dose.
• Increase to 5 mg once weekly after 4 weeks.
• Continue stepping up in 2.5 mg increments (to 7.5 mg, 10 mg, 12.5 mg, or 15 mg) every 4 weeks as tolerated.
• Maintenance doses range from 5 mg to 15 mg weekly, chosen based on tolerability and clinical response.

Your prescriber will determine the right dose and escalation pace for you. If a dose is missed, the manufacturer advises taking it within 4 days of the scheduled day. If more than 4 days have passed, skip the missed dose and take the next one on your regular day. Do not double up. Store pens in the refrigerator when unopened, and follow the pen-specific guidelines for room-temperature use.

Side effects and safety

Most side effects are gastrointestinal, tend to be dose-related, and typically improve as the body adjusts to each new dose level.

Common side effects:

• Nausea, vomiting, diarrhea, constipation
• Decreased appetite, abdominal pain, indigestion
• Injection-site reactions

Serious but less common risks:

• Boxed warning for thyroid C-cell tumors: Based on rodent studies, tirzepatide carries a warning about the risk of thyroid C-cell tumors. Mounjaro should not be used by anyone with a personal or family history of medullary thyroid carcinoma or MEN2.
• Pancreatitis: Stop the medication and contact your care team if you experience persistent, severe abdominal pain.
• Gallbladder disease: Including gallstones and cholecystitis, particularly with rapid weight loss.
• Acute kidney injury: Usually related to dehydration from persistent vomiting or diarrhea.
• Hypoglycemia: Risk increases when combined with insulin or sulfonylureas.

Side effects are most noticeable during the dose escalation phase and often ease once the body adjusts. For broader safety context across this drug class, see weight loss drug safety. Because the GI side-effect pattern overlaps closely with semaglutide, our Ozempic side effects guide is also a useful reference for what to expect during titration.

Cost and insurance coverage

In the U.S., Mounjaro’s list price is roughly $1,000 or more per month for a four-week supply of pens, depending on the dose and pharmacy. Actual out-of-pocket costs depend on your insurance plan and diagnosis.

• For type 2 diabetes: Insurance coverage is more common because Mounjaro has an FDA-approved indication for this condition. Prior authorization is still typical.
• For weight loss (off-label): Coverage is much less consistent. Many insurers will not cover Mounjaro when prescribed off-label for weight management. Your prescriber may need to document medical necessity or consider Zepbound, which has an FDA-approved weight management indication.
• Manufacturer savings: Eli Lilly has offered a Mounjaro savings card for eligible patients with commercial insurance.
• Compounded tirzepatide: Compounded versions of tirzepatide are not FDA-approved and have not been evaluated for safety, efficacy, or quality. The FDA has issued warnings about dosing errors and sterility concerns with some compounded products.

Plan for ongoing monthly costs for as long as you remain on therapy, plus clinician visits and any labs your prescriber orders.

Mounjaro vs Zepbound

Mounjaro and Zepbound contain the same active ingredient: tirzepatide. The key difference is the approved indication.

Because the molecule is identical, the clinical effects, side effects, and dose escalation are the same. Your prescriber will choose one based on your diagnosis, insurance coverage, and the approved indication that fits your situation. For a detailed comparison of the two main GLP-1 drug molecules, see semaglutide vs tirzepatide.

FAQs

Is Mounjaro FDA-approved for weight loss? No. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is the tirzepatide brand approved for chronic weight management. However, many doctors prescribe Mounjaro off-label for weight loss because the clinical trial data on weight reduction is strong.

Is Mounjaro the same drug as Zepbound? Yes, the active ingredient is identical (tirzepatide). The difference is the FDA-approved indication and, in some cases, insurance coverage. Mounjaro is labeled for type 2 diabetes; Zepbound is labeled for obesity and overweight with a weight-related condition.

How much weight can I lose on Mounjaro? In the SURMOUNT-1 trial, average weight loss ranged from about 15% to 21% of body weight over 72 weeks at the various dose levels. Individual results depend on dose, adherence, diet, activity, and starting weight.

What happens if I stop taking Mounjaro? Clinical trial data shows that weight regain is common after stopping tirzepatide. If you discontinue the medication, work with your care team on a structured maintenance plan that includes nutrition, activity, and follow-up monitoring.

Can I switch from semaglutide (Ozempic or Wegovy) to Mounjaro? Many clinicians will consider switching patients who have plateaued on semaglutide or who cannot tolerate it. Typically, a short gap occurs between the last semaglutide dose and the first tirzepatide dose, and titration restarts from the lowest Mounjaro dose.

Practical next steps

This week:

• Talk to your prescriber about whether Mounjaro or Zepbound is a better fit based on your diagnosis and insurance coverage.
• Check your insurance formulary to see which tirzepatide brand is covered and what prior authorization requirements apply.
• Start a simple log of your current weight, appetite patterns, and any relevant health metrics so you have baseline data.

What to track once you start:

• Weekly weight trend and appetite changes.
• GI symptoms (nausea, vomiting, diarrhea, constipation) and daily hydration.
• Protein intake, physical activity, and sleep quality.

How to know it is working:

• Appetite feels noticeably lower, and portion sizes are easier to manage.
• Weight loss accumulates steadily over months rather than appearing as sudden large drops.
• Side effects peak briefly after each dose increase, then ease within a week or two.

How this article was researched

This article draws on the SURMOUNT-1 and SURMOUNT-2 randomized clinical trials, the FDA approval history for tirzepatide, and the FDA prescribing information for Mounjaro and Zepbound. Safety summaries reflect labeled warnings and postmarketing communications. Cost and coverage details reflect publicly available manufacturer and payer information at the time of writing.